Advertisement

Cancer Immunology, Immunotherapy

, Volume 68, Issue 4, pp 533–544 | Cite as

Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice

  • Elodie PliquetEmail author
  • Claude Ruffie
  • Marie Escande
  • Jessie Thalmensi
  • Valérie Najburg
  • Chantal Combredet
  • Thomas Bestetti
  • Marion Julithe
  • Christelle Liard
  • Thierry Huet
  • Simon Wain-Hobson
  • Frédéric Tangy
  • Pierre Langlade-Demoyen
Original Article

Abstract

Cancer immunotherapy is seeing an increasing focus on vaccination with tumor-associated antigens (TAAs). Human telomerase (hTERT) is a TAA expressed by most tumors to overcome telomere shortening. Tolerance to hTERT can be easily broken both naturally and experimentally and hTERT DNA vaccine candidates have been introduced in clinical trials. DNA prime/boost strategies have been widely developed to immunize efficiently against infectious diseases. We explored the use of a recombinant measles virus (MV) hTERT vector to boost DNA priming as recombinant live attenuated measles virus has an impressive safety and efficacy record. Here, we show that a MV-TERT vector can rapidly and strongly boost DNA hTERT priming in MV susceptible IFNAR/CD46 mouse models. The cellular immune responses were Th1 polarized. No humoral responses were elicited. The 4 kb hTERT transgene did not impact MV replication or induction of cell-mediated responses. These findings validate the MV-TERT vector to boost cell-mediated responses following DNA priming in humans.

Keywords

Cancer Immunotherapy hTERT Measles virus vaccine T-cell responses 

Abbreviations

AP

Alkaline phosphatase

ATU

Additional transcription unit

BCIP

5-Bromo-4-chloro-3-indolyl phosphate

CBA

Cytometric beads array

MOI

Multiplicity of infection

MV

Measle virus

NBT

Nitro blue tetrazolium chloride

PVDF

Polyvinylidene fluoride

ROI

Region of interest

Tg

Transgenic

TMB

3,3′,5,5′-Tetramethylbenzidine

Ubi

Ubiquitin

UCP

Universal cancer peptide

Notes

Acknowledgements

The authors would like to thank Ludovic Bourré, Anne-Sophie Pailhes-Jimenez, Emanuèle Bourges, Rahima Youssi and Pascal Clayette for experimental and editorial help, and the staff of the Institut Pasteur’s animal facilities and imaging platform. Funding was provided by Association Nationale de la Recherche et de la Technologie (Grant no. 2012/0152).

Author contributions

SW-H, FT and PL-D conceived the project. They also shared their knowledge and experience to help EP with the experimental program design. EP performed and analyzed the experiments under the supervision of CL and TH. EP and CR carried out mice experiments. VN and CC constructed the recombinant measles telomerase virus. ME, JT, TB and MJ provided technical help. EP analysed all the data and wrote the manuscript together with SW-H and FT. All authors viewed and approved the final version of the manuscript.

Funding

We would like to thank Shannon A. Fairbanks and Bernardo Fort Brescia for their unswerving support. Elodie Pliquet was supported by an industrial Ph.D. fellowship from the French National Association of Research and Technology (ANRT).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and ethical standards

All protocols have been submitted and approved by the Pasteur Institute office of laboratory animal care CETEA no. 89 under the references 2013-0026 on February 01st, 2013 and 2014-0061 on October 07th, 2015 and by French Committee for Hygiene, Safety and Working Conditions (CHSCT) under the reference 07.157 on April 10th, 2007 and 16.0013 on January 8th, 2016. All in vivo experiments were conducted in strict accordance with good animal practice and complied with local animal experimentation and ethics committee guidelines of the Pasteur Institute (agreement no. 75-15-01 delivered on the 06th September 2013 and no. A75-15-01-1 on 18th August 2014) and Directive 2010/63/EU on the harmonization of laws, regulations and administrative provisions relating to the protection of animals.

Animal source

IFNAR/CD46 (IFN-α/βR−/− CD46+/−) mouse strain used for immunization experiments was generated by Frédéric Tangy’s team by cross-breeding and backcross between FVB/CD46+/− mice (gift from F. Grosveld, Erasmus University, Rotterdam, The Netherlands) and 129sv IFN-α/βR−/− mice which lack the type I IFN receptor (gift from M. Aguet, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland). HHD/IFNAR/CD46 (HHD+/+ CD46+/− IFN-α/βR−/−) mouse strain was generated by Frédéric Tangy’s team by cross-breeding and backcross between HHD mice (human β2m–HLA-A2.1 α1α2-H-2Dbα3-transmembrane and H-2Db−/−β2mb−/− double knockout; mice generated at Pasteur Institute by François Lemonnier) and IFNAR/CD46 mice.

Cell line authentication

HEK-293-T7-MV cell line was produced, provided and patented by Frédéric Tangy and the Institut Pasteur. Vero cells were provided by the American Type Culture Collection (ATCC®) under reference number CCL-81™.

References

  1. 1.
    Eggermont AMM, Kroemer G, Zitvogel L (2013) Immunotherapy and the concept of a clinical cure. Eur J Cancer 49(14):2965–2967.  https://doi.org/10.1016/j.ejca.2013.06.019 CrossRefGoogle Scholar
  2. 2.
    Bluestone JA, Small EJ (2012) The future of cancer treatment: will it include immunotherapy? Cancer Cell 22(1):7–8.  https://doi.org/10.1016/j.ccr.2012.06.009 CrossRefGoogle Scholar
  3. 3.
    Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8(1):62–73.  https://doi.org/10.1038/nrmicro2240 CrossRefGoogle Scholar
  4. 4.
    Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P (2000) Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 74(1):11–25.  https://doi.org/10.1016/S0165-2478(00)00244-3 CrossRefGoogle Scholar
  5. 5.
    Larocca C, Schlom J (2011) Viral vector-based therapeutic cancer vaccines. Cancer J 17(5):359–371.  https://doi.org/10.1097/PPO.0b013e3182325e63 CrossRefGoogle Scholar
  6. 6.
    Moss WJ, Griffin DE (2012) Measles. Lancet 379(9811):153–164.  https://doi.org/10.1016/S0140-6736(10)62352-5 CrossRefGoogle Scholar
  7. 7.
    Hilleman MR (2001) Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 20(5–6):651–665.  https://doi.org/10.1016/S0264-410X(01)00384-X CrossRefGoogle Scholar
  8. 8.
    Guillerme J-B, Gregoire M, Tangy F, Fonteneau J-F (2013) Antitumor virotherapy by attenuated measles virus (MV). Biology 2(2):587.  https://doi.org/10.3390/biology2020587 CrossRefGoogle Scholar
  9. 9.
    Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357(19):1903–1915.  https://doi.org/10.1056/NEJMoa066092 CrossRefGoogle Scholar
  10. 10.
    Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, Wild P, Viret JF, Glueck R, Billeter MA, Naim HY (2007) Attenuated measles virus as a vaccine vector. Vaccine 25(16):2974–2983.  https://doi.org/10.1016/j.vaccine.2007.01.064 CrossRefGoogle Scholar
  11. 11.
    Brandler S, Tangy F (2008) Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 31(2–3):271–291.  https://doi.org/10.1016/j.cimid.2007.07.012 CrossRefGoogle Scholar
  12. 12.
    Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, Despres P, Tauber E, Jilma B, Tangy F (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15(5):519–527.  https://doi.org/10.1016/S1473-3099(15)70043-5 CrossRefGoogle Scholar
  13. 13.
    Knuchel MC, Marty RR, Morin TN, Ilter O, Zuniga A, Naim HY (2013) Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector. Hum Vaccines Immunother 9(3):599–606.  https://doi.org/10.4161/hv.23241 CrossRefGoogle Scholar
  14. 14.
    Russell SJ, Peng KW (2009) Measles virus for cancer therapy. Curr Top Microbiol Immunol 330:213–241Google Scholar
  15. 15.
    Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E (2009) Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69(1):82–91.  https://doi.org/10.1002/pros.20857 CrossRefGoogle Scholar
  16. 16.
    Zanetti M (2017) A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol 14(2):115–128.  https://doi.org/10.1038/nrclinonc.2016.67 CrossRefGoogle Scholar
  17. 17.
    Collins K, Mitchell JR (2002) Telomerase in the human organism. Oncogene 21(4):564–579.  https://doi.org/10.1038/sj.onc.1205083 CrossRefGoogle Scholar
  18. 18.
    Low KC, Tergaonkar V (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 38(9):426–434.  https://doi.org/10.1016/j.tibs.2013.07.001 CrossRefGoogle Scholar
  19. 19.
    Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33(5):787–791.  https://doi.org/10.1016/S0959-8049(97)00062-2 CrossRefGoogle Scholar
  20. 20.
    Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS (2006) Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer 94(10):1452–1459.  https://doi.org/10.1038/sj.bjc.6603110 CrossRefGoogle Scholar
  21. 21.
    Lü M-H, Deng J-Q, Cao Y-L, Fang D-C, Zhang YAO, Yang S-M (2012) Prognostic role of telomerase activity in gastric adenocarcinoma: a meta-analysis. Exp Ther Med 3(4):728–734.  https://doi.org/10.3892/etm.2012.471 CrossRefGoogle Scholar
  22. 22.
    Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Gourgoulianis KI, Germenis AE (2010) Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer. Immunol Cell Biol 88(5):575–585.  https://doi.org/10.1038/icb.2010.8 CrossRefGoogle Scholar
  23. 23.
    Thalmensi J, Pliquet E, Liard C, Escande M, Bestetti T, Julithe M, Kostrzak A, Pailhes-Jimenez A-S, Bourges E, Loustau M, Caumartin J, Lachgar A, Huet T, Wain-Hobson S, Langlade-Demoyen P (2016) Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology 5(3):e1083670.  https://doi.org/10.1080/2162402X.2015.1083670 CrossRefGoogle Scholar
  24. 24.
    Rice J, Ottensmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8(2):108–120.  https://doi.org/10.1038/nrc2326 CrossRefGoogle Scholar
  25. 25.
    Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL (2010) Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses 2(2):435–467.  https://doi.org/10.3390/v2020435 CrossRefGoogle Scholar
  26. 26.
    Hallengärd D, Lum F-M, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LFP, Esteban M, Liljeström P (2014) Prime-boost immunization strategies against chikungunya virus. J Virol 88(22):13333–13343.  https://doi.org/10.1128/JVI.01926-14 CrossRefGoogle Scholar
  27. 27.
    Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V (2005) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113(2):259–266.  https://doi.org/10.1002/ijc.20569 CrossRefGoogle Scholar
  28. 28.
    Kim SB, Ahn JH, Kim J, Jung KH (2015) A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. Mol Ther Methods Clin Dev 2:15031.  https://doi.org/10.1038/mtm.2015.31 CrossRefGoogle Scholar
  29. 29.
    Drosopoulos WC, Prasad VR (2007) The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity. Nucleic Acids Res 35(4):1155–1168.  https://doi.org/10.1093/nar/gkm002 CrossRefGoogle Scholar
  30. 30.
    Yang Y, Chen Y, Zhang C, Huang H, Weissman SM (2002) Nucleolar localization of hTERT protein is associated with telomerase function. Exp Cell Res 277(2):201–209.  https://doi.org/10.1006/excr.2002.5541 CrossRefGoogle Scholar
  31. 31.
    Bachmair A, Finley D, Varshavsky A (1986) In vivo half-life of a protein is a function of its amino-terminal residue. Science 234(4773):179–186.  https://doi.org/10.1126/science.3018930 CrossRefGoogle Scholar
  32. 32.
    Bankamp B, Takeda M, Zhang Y, Xu W, Rota PA (2011) Genetic Characterization of measles vaccine strains. J Infect Dis 204(suppl 1):S533–S548.  https://doi.org/10.1093/infdis/jir097 CrossRefGoogle Scholar
  33. 33.
    Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA (1995) Rescue of measles viruses from cloned DNA. EMBO J 14(23):5773–5784CrossRefGoogle Scholar
  34. 34.
    Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77(21):11546–11554.  https://doi.org/10.1128/JVI.77.21.11546-11554.2003 CrossRefGoogle Scholar
  35. 35.
    Lorin C, Delebecque F, Labrousse V, Da Silva L, Lemonnier F, Brahic M, Tangy F (2005) A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23(36):4463–4472.  https://doi.org/10.1016/j.vaccine.2005.04.024 CrossRefGoogle Scholar
  36. 36.
    Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185(12):2043–2051.  https://doi.org/10.1084/jem.185.12.2043 CrossRefGoogle Scholar
  37. 37.
    Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99(19):12275–12280.  https://doi.org/10.1073/pnas.182418399 CrossRefGoogle Scholar
  38. 38.
    Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotevi O (2012) Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res Off J Am Assoc Cancer Res 18(22):6284–6295.  https://doi.org/10.1158/1078-0432.CCR-12-0896 CrossRefGoogle Scholar
  39. 39.
    Komarova AV, Combredet C, Meyniel-Schicklin L, Chapelle M, Caignard G, Camadro JM, Lotteau V, Vidalain PO, Tangy F (2011) Proteomic analysis of virus–host interactions in an infectious context using recombinant viruses. Mol Cell Proteom 10(12):M110 007443.  https://doi.org/10.1074/mcp.M110.007443 CrossRefGoogle Scholar
  40. 40.
    Durward M, Harms J, Splitter G (2010) Antigen specific killing assay using CFSE labeled target cells. J Vis Exp.  https://doi.org/10.3791/2250 Google Scholar
  41. 41.
    Lu S (2009) Heterologous prime-boost vaccination. Curr opin immunol 21(3):346–351. https://doi.org/10.1016/j.coi.2009.05.016 CrossRefGoogle Scholar
  42. 42.
    Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, Akira S (2008) TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451(7179):725–729.  https://doi.org/10.1038/nature06537 CrossRefGoogle Scholar
  43. 43.
    Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, Ishii KJ (2011) Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 11(6):479–484.  https://doi.org/10.2174/156652311798192815 CrossRefGoogle Scholar
  44. 44.
    Tasaki T, Sriram SM, Park KS, Kwon YT (2012) The N-end rule pathway. Annu Rev Biochem 81:261–289.  https://doi.org/10.1146/annurev-biochem-051710-093308 CrossRefGoogle Scholar
  45. 45.
    Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R (1998) Measles virus spread and pathogenesis in genetically modified mice. J Virol 72(9):7420–7427Google Scholar
  46. 46.
    Ludlow M, de Vries RD, Lemon K, McQuaid S, Millar E, van Amerongen G, Yuksel S, Verburgh RJ, Osterhaus AD, de Swart RL, Duprex WP (2013) Infection of lymphoid tissues in the macaque upper respiratory tract contributes to the emergence of transmissible measles virus. J Gen Virol 94(Pt 9):1933–1944.  https://doi.org/10.1099/vir.0.054650-0 CrossRefGoogle Scholar
  47. 47.
    Woodland DL (2004) Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25(2):98–104.  https://doi.org/10.1016/j.it.2003.11.009 CrossRefGoogle Scholar
  48. 48.
    Palucka K, Ueno H, Banchereau J (2011) Recent developments in cancer vaccines. J Immunol 186(3):1325–1331.  https://doi.org/10.4049/jimmunol.0902539 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Invectys, Pépinière Paris Santé CochinParisFrance
  2. 2.Molecular Retrovirology UnitInstitut Pasteur, CNRS-URA 3015ParisFrance
  3. 3.Viral Genomics and Vaccination UnitInstitut Pasteur, CNRS-UMR 3965ParisFrance

Personalised recommendations